171 related articles for article (PubMed ID: 24618694)
1. Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Locati LD; Perrone F; Cortelazzi B; Imbimbo M; Bossi P; Potepan P; Civelli E; Rinaldi G; Quattrone P; Licitra L; Pilotti S
Cancer Biol Ther; 2014 Jun; 15(6):678-82. PubMed ID: 24618694
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.
Locati LD; Perrone F; Cortelazzi B; Lo Vullo S; Bossi P; Dagrada G; Quattrone P; Bergamini C; Potepan P; Civelli E; Fallai C; Pilotti S; Licitra L
Head Neck; 2016 May; 38(5):724-31. PubMed ID: 25522335
[TBL] [Abstract][Full Text] [Related]
3. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C; Tada Y; Takahashi H; Nagao T; Ojiri H; Masubuchi T; Matsuki T; Miura K; Kawakita D; Hirai H; Hoshino E; Kamata S; Saotome T
Ann Oncol; 2018 Apr; 29(4):979-984. PubMed ID: 29211833
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
7. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
9. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients].
Salvador C; Planas J; Raventós C; Ropero J; Placer J; López MA; Morote J
Actas Urol Esp; 2012 Apr; 36(4):205-9. PubMed ID: 22178349
[TBL] [Abstract][Full Text] [Related]
10. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
11. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
[TBL] [Abstract][Full Text] [Related]
12. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
[No Abstract] [Full Text] [Related]
13. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
15. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
[No Abstract] [Full Text] [Related]
17. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.
Soper MS; Iganej S; Thompson LD
Head Neck; 2014 Jan; 36(1):E4-7. PubMed ID: 23720164
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Colombo E; Calareso G; Mariani L; Quattrone P; Alfieri S; Bossi P; Platini F; Capone I; Licitra L
J Clin Oncol; 2021 Dec; 39(36):4061-4068. PubMed ID: 34597119
[TBL] [Abstract][Full Text] [Related]
20. Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells.
Castoria G; Giovannelli P; Di Donato M; Hayashi R; Arra C; Appella E; Auricchio F; Migliaccio A
PLoS One; 2013; 8(10):e76899. PubMed ID: 24130806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
